National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 101021 [2024-29380]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 240 / Friday, December 13, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSK9W7S144PROD with NOTICES
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Human Leukocyte Antigen
(HLA) and Killer-cell Immunoglobulin-like
Receptor (KIR) Region Genomics in ImmuneMediated Diseases (U01 Clinical Trial Not
Allowed).
Date: February 5, 2025.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Maryam Rohani, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20892, (301) 761–6656, maryam.rohani@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–29380 Filed 12–12–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:12 Dec 12, 2024
Jkt 265001
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Project: SAMHSA Certified Community
Behavioral Health Clinic—Expansion
(CCBHC–E) Grant Program Evaluation
(OMB No. 0930–XXXX)—NEW
COLLECTION
In FY 2022, SAMHSA awarded two
new cohorts of its CCBHC-Expansion
program, one for clinics interested in
becoming CCBHCs that need planning
and support to come into compliance
with CCBHC Certification Criteria, and
another for established CCBHCs seeking
to expand, improve, and advance their
services. The purpose of the CCBHC–E
grants is to address problems of access,
coordination, and quality of behavioral
health care by establishing a standard
definition and criteria for organizations
certified as CCBHCs to ensure that all
service recipients have access to a
common set of comprehensive,
coordinated services, with the ultimate
goal of decreasing disparities in care
and outcomes across communities.
SAMHSA is requesting clearance for
eleven data collection instruments and
forms related to the implementation and
impact studies to be conducted as part
of an evaluation of these cohorts. Data
collected in this evaluation will help
SAMHSA assess the degree to which
activities at the clinic level and systems
level affect the development,
implementation, and sustainment of
CCBHCs consistent with the
certification criteria and the impacts of
model adoption on client outcomes.
1. SAMHSA has developed a grantee
web survey that will be administered
twice to all 298 grant project directors,
once during a first option year and again
during a third option year. The survey
consists of 76 questions the first time it
is administered and 68 questions the
second time it is administered. The
survey includes mostly binary or
multiple-choice response options and a
limited number of open-ended
questions. The survey will enable
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
101021
respondents to complete the data
collection instrument at a location and
time of their choice, and its built-in
editing checks and programmed skips
will reduce response errors. SAMHSA
estimates the web survey will take no
more than 45 minutes to complete and
expects a 100 percent response rate, for
a total of 298 completed grantee
surveys. Grantees will provide valuable
insights into their experience with the
CCBHC model; if they are not
conducted, SAMHSA will not have
adequate information to evaluate the
extent to which Planning, Development,
and Implementation (PDI) grantees
come into full compliance with the
certification criteria and Improvement
and Advancement (IA) grantees sustain
the model in a manner that is consistent
with the CCBHC certification criteria.
2. SAMHSA has developed a protocol
for annual interviews with all 26 grantee
Government Project Officers (GPO)s
during three option years. Interviews
will last approximately one hour and
focus on the types of support grantees
need to successfully implement the
model in the future and identify specific
components of the certification criteria
that were challenging for grantees to
implement. SAMHSA will offer to
conduct individual interviews or meet
with groups of GPOs during regularly
scheduled meetings. GPOs will provide
valuable insights into CCBHC model
implementation and factors that
facilitate or impede implementation; if
they are not conducted, SAMHSA will
not glean essential insights into
contextual factors that affect
implementation of the CCBHC model,
including adaptations grantees make to
the model to align with their local
service delivery system, grantee
characteristics that might contribute to
successful implementation, and the
types of support grantees need to
successfully implement the model in
the future and the specific components
of the certification criteria that were
challenging for grantees to implement.
3. SAMHSA has developed a protocol
for interviews with representatives from
50 organizations that support adults,
youth, and family members with lived
experience over the course of the first
three option years. Interviews will last
approximately one hour. State
consumer, youth, and family member
organizations will provide valuable
insights into their own involvement in
the planning and development of the
model in respective states, and the
perspectives of adults and youth who
received CCBHC services and their
families on various aspects of the
CCBHC model; if they are not
conducted, SAMHSA will not
E:\FR\FM\13DEN1.SGM
13DEN1
]]>Agencies
[Federal Register Volume 89, Number 240 (Friday, December 13, 2024)]
[Notices]
[Page 101021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29380]
[[Page 101021]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Human Leukocyte Antigen (HLA) and
Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in
Immune-Mediated Diseases (U01 Clinical Trial Not Allowed).
Date: February 5, 2025.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Maryam Rohani, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD
20892, (301) 761-6656, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: December 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-29380 Filed 12-12-24; 8:45 am]
BILLING CODE 4140-01-P
